![ophthalmic therapies ophthalmic therapies](https://static.packgene.com/wp-content/uploads/2024/06/ophthalmic-therapies.jpg)
Accelerating Development of RO-104
Kemwell Biopharma will manufacture RO-104, a novel biologic targeting three key angiogenic pathways (VEGF-A, VEGF-C, Ang-2) linked to nAMD, a leading cause of blindness. RO-104’s ability to bind these targets positions it as a first-in-class monotherapy biologic, set to transform retinal disease treatment.
Leveraging Expertise for Expedited Development
Kemwell, operating India’s first commercial cGMP facility, brings extensive protein manufacturing expertise to the partnership. Combined with RevOpsis’ innovative Rev-Mod platform, this collaboration aims to expedite the development of multispecific biologics.
“Partnering with Kemwell is a pivotal step in accelerating the development of our lead candidate, RO-104, and advancing our pipeline of innovative multispecific biologics,” said Ram Bhandari, MD, Co-founder and Interim CEO of RevOpsis. “Kemwell’s track record in high-quality biologics manufacturing, combined with our proprietary Rev-Mod platform, ensures we can deliver transformative therapies efficiently.”
Anurag Bagaria, CEO of Kemwell Biopharma, added, “We are excited to collaborate with RevOpsis to manufacture and commercialize RO-104. This partnership underscores our commitment to delivering high-quality biologics for patients in need.”
Streamlined Therapeutic Discovery to IND Submission
This alliance provides RevOpsis with a critical solution to transition from pre-clinical activities to first-in-human clinical trials, expediting RO-104 and the broader platform development. Integrating RevOpsis’ multispecific biologics platform with Kemwell’s manufacturing expertise aims to streamline therapeutic discovery to IND submission timelines.
About RO-104
RO-104, leveraging the Rev-Mod platform, is RevOpsis’ lead candidate. It addresses three key angiogenic pathways (VEGF-A, VEGF-C, Ang-2) in retinal vascular disease progression, including nAMD, representing a significant advancement in treatment supported by preclinical evidence.
About Rev-Mod Platform
The Rev-Mod Platform employs a ‘plug-and-play’ approach to expedite the discovery and development of multispecific biologics for prevalent chronic diseases. It features a library of 30 billion fully human antibody components, enabling rapid identification and assembly of multispecific candidates.
About RevOpsis Therapeutics
Founded in 2018, RevOpsis Therapeutics is a biopharmaceutical company focused on ophthalmic therapies. Leveraging its proprietary Rev-Mod Platform, RevOpsis aims to develop groundbreaking treatments for chronic diseases.
About Kemwell Biopharma
Kemwell Biopharma is a leading CDMO providing development and manufacturing services for therapeutic proteins. Located in Bangalore, India, Kemwell offers end-to-end services for biopharmaceutical development and manufacturing.
https://finance.yahoo.com/news/revopsis-secures-16-5-million-131500007.html?guccounter=1
![GMP mRNA](https://static.packgene.com/wp-content/uploads/2023/07/13.jpg)
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Beacon raises $170M to take on J&J in ocular gene therapy
Transatlantic biotech Beacon Therapeutics has raised $170 million to potentially bring a rare ophthalmology gene therapy to market in a competition with Johnson & Johnson. J&J is ahead of Beacon, having fully enrolled its late-stage test of botaretigene...
GSK Pays $430M Upfront for CureVac’s COVID-19, Flu mRNA Vaccines
GSK on Wednesday announced it is restructuring an existing collaboration agreement with German biotech CureVac, focusing on their investigational mRNA vaccines for influenza and COVID-19 while withdrawing from other infectious disease projects. Under the amended...
J&J, Legend’s Phase III Win Cements Carvykti as Earlier-Line Multiple Myeloma Treatment
Johnson & Johnson and Legend Biotech on Tuesday released interim results from the Phase III CARTITUDE-4 study, touting significant survival improvement in multiple myeloma patients after treatment with their CAR-T therapy Carvykti (ciltacabtagene autoleucel). The...
FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues
The biggest news of the week was the FDA approval of Eli Lilly’s Kisunla (donanemab) on Tuesday. While not unexpected, it was one of the year’s most highly anticipated decisions. And last week saw another big approval from the FDA—that of Verona’s novel COPD drug. But...
Related Services
![](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Plasmids GMP Services
![](https://static.packgene.com/wp-content/uploads/2023/01/10-2.png)
AAV GMP Services
![aav icon](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)